Partnervest Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Partnervest Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$547K	Buy	6,543 +60	+0.9%	+$5.32K	0.17%	104
2020 Q2	$476K	Buy	6,483 +30	+0.5%	+$1.75K	0.18%	100
2020 Q1	$274K	Buy	+6,453	New	+$333K	0.12%	142
2019 Q3	–	Sell	-4,860	Closed	-$229K	–	260
2019 Q2	$229K	Buy	+4,860	New	+$194K	0.09%	187

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Partnervest Advisory Services's CRSP Position: Q3 2020 in Review

Partnervest Advisory Services increased its CRISPR Therapeutics (CRSP) stake by 0.93% in Q3 2020, buying an estimated $5.32K and bringing the position to 6,543 shares worth $547K. The position accounts for 0.17% of the portfolio, ranked #104.

Partnervest Advisory Services first reported a position in CRSP in Q2 2019 and has held it in 4 quarters since. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

Partnervest Advisory Services held 6,543 shares of CRISPR Therapeutics worth $547K as of Q3 2020.
Partnervest Advisory Services bought 60 CRISPR Therapeutics shares in Q3 2020, an estimated $5.32K.
CRISPR Therapeutics made up 0.17% of Partnervest Advisory Services's portfolio in Q3 2020, its #104 holding.
Partnervest Advisory Services first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 4 quarters since.
310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Partnervest Advisory Services's 13F filing for Q3 2020, filed 3 Nov 2020.